Nathan W Cummins

9PUBLICATIONS
21CO-AUTHORS
Innate immunityTumour immunologyGene and molecular therapyRespiratory diseasesHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Nov 30, 2022
The BCL-2 Inhibitor Venetoclax Augments Immune Effector Function Mediated by Fas Ligand, TRAIL, and Perforin/Granzyme B, Resulting in Reduced Plasma Viremia and Decreased HIV Reservoir Size during Acute HIV Infection in a Humanized Mouse Model.

Aswath P Chandrasekar, Nathan W Cummins, Sekar Natesampillai

|Jul 20, 2022
Detecting Sources of Immune Activation and Viral Rebound in HIV Infection.

Stephen W Wietgrefe, Lijie Duan, Jodi Anderson

|Apr 08, 2021
The Combination of Venetoclax and Ixazomib Selectively and Efficiently Kills HIV-Infected Cell Lines but Has Unacceptable Toxicity in Primary Cell Models.

Alecia Alto, Sekar Natesampillai, Aswath P Chandrasekar

|Oct 19, 2020
Reactivating latent HIV with PKC agonists induces resistance to apoptosis and is associated with phosphorylation and activation of BCL2.

Andrea J French, Sekar Natesampillai, Ashton Krogman

|Nov 01, 2019
The Role of the BCL-2 Family of Proteins in HIV-1 Pathogenesis and Persistence.

Aswath P Chandrasekar, Nathan W Cummins, Andrew D Badley

|Jun 14, 2019
TRAILshort Protects against CD4 T Cell Death during Acute HIV Infection.

Sekar Natesampillai, Ana C Paim, Nathan W Cummins

Pageof 2

Frequent Collaborators

3 joint publications

Aswath P Chandrasekar

2 joint publications

Alecia Alto

1 joint publications

Stephane Hua

1 joint publications

Guinevere Q Lee